FTY720 ameliorates MOG-induced experimen
β
Dimitrios Papadopoulos; Jon Rundle; Ryan Patel; Ian Marshall; Jennifer Stretton;
π
Article
π
2010
π
John Wiley and Sons
π
English
β 593 KB
## Abstract FTY720, an oral sphingosine 1βphosphate (S1P) receptor modulator, has shown efficacy in phase II trials in patients with relapsingβremitting multiple sclerosis (MS). Although this molecule is thought to immunosuppress by inhibiting lymphocyte egress from the lymph nodes, the full spectr